14.24
0.28%
-0.255
前日終値:
$14.50
開ける:
$14.39
24時間の取引高:
7,653
Relative Volume:
0.13
時価総額:
$25.63M
収益:
-
当期純損益:
$-4.85M
株価収益率:
-20.32
EPS:
-0.7012
ネットキャッシュフロー:
$-3.95M
1週間 パフォーマンス:
-12.73%
1か月 パフォーマンス:
-5.12%
6か月 パフォーマンス:
+129.52%
1年 パフォーマンス:
+92.68%
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
CVKD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
CVKD | 14.45 | 25.63M | 0 | -4.85M | -3.95M | -0.7012 |
VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.54 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.23 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.40 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cadrenal Therapeutics Inc (CVKD) 最新ニュース
CVKD: Recent Financings Raise $9.8 Million… - MSN
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - StockTitan
(CVKD) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com
Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data | CVKD Stock News - StockTitan
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS - PR Newswire
Cadrenal shares gain; analyst highlights Buy rating and key LVAD trial advancements - Investing.com Canada
Cadrenal Therapeutics Provides Third-Quarter Corporate Update - Defense World
Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics Raises $9.8M, Advances Unique Anticoagulant Drug Development | CVKD Stock News - StockTitan
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE - PR Newswire
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance
(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin - TipRanks
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - PR Newswire
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - PR Newswire
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2% - MarketBeat
Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) - MarketBeat
Long Term Trading Analysis for (CVKD) - Stock Traders Daily
Jacksonville stocks rise as market hits record highs - Jacksonville Daily Record
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8% - MarketBeat
Cadrenal Therapeutics Inc (CVKD-Q) QuotePress Release - The Globe and Mail
Where are the Opportunities in (CVKD) - Stock Traders Daily
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy - TipRanks
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference - Kilgore News Herald
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Forecasted to Earn Q3 2024 Earnings of ($2.18) Per Share - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Trading Down 4.1% - Defense World
WATCH LIVE: Fed Chair Jerome Powell speaks after a 50bp interest rate cut - Investing.com
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data - MSN
Cadrenal Therapeutics (CVKD) Stock Rallies In After-Market Trading Ahead Of Regulatory Meeting - Stocks Telegraph
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - MarketBeat
Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland - MSN
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Cadrenal Therapeutics regains Nasdaq compliance - Investing.com India
Cadrenal gears up for FDA talks on heart drug trial - Investing.com India
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients - PR Newswire
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients - PR Newswire
Upcoming Stock Splits This Week (August 19 to August 23) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested - MSN
Cadrenal Therapeutics to Implement 1-for-15 Reverse Stock Split - Marketscreener.com
Cadrenal announces 1-for-15 reverse stock split By Investing.com - Investing.com Australia
Cadrenal announces 1-for-15 reverse stock split - Investing.com
Cadrenal Therapeutics Inc: Analyzing CVKD Stock Trends - The InvestChronicle
CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cadrenal Therapeutics to Present at Upcoming Investor Conferences - Longview News-Journal
Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now - Yahoo Finance
Q3 2024 Earnings Estimate for Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Issued By HC Wainwright - Defense World
Cadrenal Therapeutics Inc (CVKD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):